Compare Cytokinetics Inc (CYTK) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Prudential PLC — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Prudential PLC trades at $24.03 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 3.3× Cytokinetics Inc's market cap, and Prudential PLC pays a 2.33% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Prudential PLC for 119 Days on average.
| CYTK | PUK | |
|---|---|---|
Market Cap | $8.62B | $28.84B |
Volume | 2,594,626 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $87.26 | $33.61 |
52-Week Low | $54.76 | $23.54 |
Typical Hold Time | 19 Days | 119 Days |
Enterprise Value | $8.72B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
PUK trades at $23.54, down 4.31% today, amid bearish technical signals. The company shows strong fundamentals with revenue growth from $16.2B in 2024 to $27.4B in 2025 and net income of $4.0B. Valuation ratios appear attractive with P/E of 8.28 and P/S of 1.01. Recent news highlights strategic shifts including emerging-market exits and a $3B capital rotation plan. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook balances solid profitability and growth against technical weakness and macroeconomic risks. Investment appeal lies in undervalued metrics and strategic refocusing, but near-term price pressure and execution risks on new initiatives warrant caution. The stock offers value for long-term investors if the company delivers on its five-year strategic targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
